Vivoryon Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Vivoryon Therapeutics wird ein Gewinn- und Umsatzwachstum von 5.1% bzw. 106.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 7.7% pro Jahr wachsen soll.

Wichtige Informationen

5.1%

Wachstumsrate der Gewinne

7.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	43.1%
Wachstumsrate der Einnahmen	106.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	24 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

May 28

Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

May 04

Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

Sep 02

Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Jan 26

Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

Sep 16

We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth

May 10

Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?

Mar 11

We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely

Jan 14

Gewinn- und Umsatzwachstumsprognosen

ENXTAM:VVY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-21	-20	-18	2
12/31/2025	N/A	-18	-17	-17	3
12/31/2024	N/A	-23	-24	-24	3
6/30/2024	-4	-31	-15	-15	N/A
3/31/2024	-4	-30	-19	-18	N/A
12/31/2023	-4	-28	-22	-22	N/A
9/30/2023	-2	-27	-27	-27	N/A
6/30/2023	N/A	-26	-32	-32	N/A
3/31/2023	N/A	-27	-27	-27	N/A
12/31/2022	N/A	-28	-22	-22	N/A
9/30/2022	N/A	-26	-20	-20	N/A
6/30/2022	11	-14	-15	-15	N/A
3/31/2022	11	-13	-13	-13	N/A
12/31/2021	11	-13	-11	-11	N/A
9/30/2021	11	-12	-11	-11	N/A
6/30/2021	N/A	-21	-14	-14	N/A
3/31/2021	N/A	-19	-14	-14	N/A
12/31/2020	N/A	-17	-15	-14	N/A
9/30/2020	N/A	-15	-15	-15	N/A
6/30/2020	N/A	-12	-15	-15	N/A
3/31/2020	N/A	-10	-13	-13	N/A
12/31/2019	N/A	-8	-12	-12	N/A
9/30/2019	N/A	-7	-9	-9	N/A
6/30/2019	N/A	-7	-6	-6	N/A
3/31/2019	N/A	-7	-7	-7	N/A
12/31/2018	N/A	-8	-7	-7	N/A
9/30/2018	N/A	-8	-8	-8	N/A
6/30/2018	N/A	-8	-9	-9	N/A
3/31/2018	N/A	-8	N/A	-10	N/A
12/31/2017	N/A	-8	N/A	-12	N/A
9/30/2017	N/A	-10	N/A	-13	N/A
6/30/2017	N/A	-12	N/A	-14	N/A
3/31/2017	N/A	-13	N/A	-14	N/A
12/31/2016	N/A	-14	N/A	-13	N/A
9/30/2016	N/A	-14	N/A	-13	N/A
6/30/2016	N/A	-13	N/A	-13	N/A
3/31/2016	N/A	-13	N/A	-13	N/A
12/31/2015	N/A	-14	N/A	-12	N/A
9/30/2015	N/A	-14	N/A	-13	N/A
6/30/2015	N/A	-14	N/A	-13	N/A
3/31/2015	N/A	-13	N/A	-12	N/A
12/31/2014	N/A	-11	N/A	-11	N/A
9/30/2014	N/A	-10	N/A	-9	N/A
6/30/2014	N/A	-9	N/A	-7	N/A
3/31/2014	N/A	-9	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VVY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VVY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VVY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VVY wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: VVY wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von VVY in 3 Jahren voraussichtlich hoch sein wird

Vivoryon Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 23% to €23.23

Price target increased by 26% to €62.00

Price target decreased by 26% to €44.17

No longer forecast to breakeven

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

Recent updates

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Price target decreased by 23% to €23.23

New major risk - Financial position

Vivoryon Therapeutics N.V. to Report First Half, 2024 Results on Sep 12, 2024

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V.(ENXTAM:VVY) dropped from Netherlands ASCX AMS Small Cap Index

New minor risk - Profitability

Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Vivoryon Therapeutics N.V. to Report Q1, 2024 Results on May 23, 2024

Vivoryon Therapeutics N.V., Annual General Meeting, Jun 21, 2024

Vivoryon Therapeutics N.V. to Report Fiscal Year 2023 Results on Apr 24, 2024

Vivoryon Therapeutics N.V Announces Resignation of Board of Directors

Vivoryon Therapeutics N.V. Provides Update on Viviad Phase 2B Study of Varoglutamstat in Early Alzheimer’S Disease

Price target increased by 26% to €62.00

Vivoryon Therapeutics N.V. Announces Executive Changes

Vivoryon Therapeutics N.V. to Report Q3, 2023 Results on Dec 06, 2023

Chairman of the Management Board recently bought €158k worth of stock

Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision

New major risk - Share price stability

Price target decreased by 26% to €44.17

Less than half of directors are independent

Vivoryon Therapeutics N.V. Announces Board Appointments

Vivoryon Therapeutics N.V. to Report First Half, 2023 Results on Sep 07, 2023

Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s Disease

Less than half of directors are independent

Vivoryon Therapeutics N.V. Approves Board Appointments

Vivoryon Therapeutics N.V. Announces Resignation of Ulrich Dauer as CEO

Vivoryon Therapeutics N.V., Annual General Meeting, Jun 21, 2023

No longer forecast to breakeven

Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

Price target increased to €60.00

No independent directors

Vivoryon Therapeutics N.V. to Report First Half, 2022 Results on Sep 30, 2022

Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

Vivoryon Therapeutics Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O (News with Additional Features)

Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2B Study of Varoglutamstat in AD

Vivoryon Therapeutics N.V. Announces the Appointment of Dr. Claudia Riedl and Samir Shah to its Non-Executive Board of Directors

Vivoryon Therapeutics N.V. to Report Q1, 2022 Results on Jun 15, 2022

No longer forecast to breakeven

Vivoryon Therapeutics N.V., Annual General Meeting, Jun 22, 2022

Price target increased to €60.00

Vivoryon Therapeutics N.V. to Report Fiscal Year 2021 Results on Apr 28, 2022

Vivoryon Therapeutics N.V. and Simcere Pharmaceutical Group Ltd Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease

Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

Forecast to breakeven in 2025

We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth

Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?

We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely

New 90-day high: €9.58

Vivoryon Therapeutics AG to Report Q1, 2021 Results on Jun 01, 2021

New 90-day high: €5.70

New 90-day high - €4.60

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken